Free Trial
TSE:AEZS

Aeterna Zentaris (AEZS) Stock Price, News & Analysis

Aeterna Zentaris logo
C$5.10
0.00 (0.00%)
(As of 10/11/2024)

About Aeterna Zentaris Stock (TSE:AEZS)

Key Stats

Today's Range
C$5.10
C$5.10
50-Day Range
C$4.84
C$8.33
52-Week Range
C$5.40
C$16.08
Volume
286 shs
Average Volume
1,137 shs
Market Capitalization
C$15.61 million
P/E Ratio
N/A
Dividend Yield
2.79%
Price Target
N/A
Consensus Rating
N/A

Company Overview

Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests in Canada, Switzerland, Ireland, Denmark, Germany, the United States, and internationally. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of patients with adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as endocrinology and oncology indications; AEZS-150, a delayed clearance parathyroid hormone fusion polypeptide that is in preclinical trial for the treatment of chronic hypoparathyroidism; and AEZS-130 that is in preclinical trial for the treatment of amyotrophic lateral sclerosis. The company also has a license and research agreement with University of Wuerzburg to develop, manufacture, and commercialize AIM biologicals for the treatment of neuromyelitis optica spectrum disorder; and for pre-clinical development towards the potential treatment of Parkinson's disease. In addition, it has a license agreement with Consilient Health Ltd. and NK MEDITECH Ltd. for the development and commercialization of macimorelin; a distribution and commercialization agreement with Er-Kim Pharmaceuticals Bulgaria Eood for the commercialization of macimorelin for the diagnosis of growth hormone deficiency in children and adults; as well as The University of Sheffield, the United Kingdom for the development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of chronic hypoparathyroidism. Aeterna Zentaris Inc. was incorporated in 1990 and is headquartered in Toronto, Canada.

Receive AEZS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aeterna Zentaris and its competitors with MarketBeat's FREE daily newsletter.

AEZS Stock News Headlines

Closing Bell: Aeterna Zentaris Inc up on Monday (AEZS)
AEZS:CA Aeterna Zentaris Inc.
Crypto Crash Ahead? (27 Experts Weigh In)
Your Portfolio Could Be at RISK Emergency summit reveals crypto could save you!
See More Headlines

AEZS Stock Analysis - Frequently Asked Questions

Aeterna Zentaris' stock was trading at C$2.57 at the beginning of the year. Since then, AEZS shares have increased by 98.4% and is now trading at C$5.10.
View the best growth stocks for 2024 here
.

Shares of AEZS stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Aeterna Zentaris investors own include Meta Platforms (META), Novavax (NVAX), Verizon Communications (VZ), Western Uranium & Vanadium (WUC), Air Canada (AC), Affirm (AFRM) and AutoZone (AZO).

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
Pharmaceutical Products
CIK
N/A
Fax
N/A
Employees
20
Year Founded
N/A

Profitability

Net Income
C$-18,050,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
C$2.37 million
Cash Flow
C$11.13 per share
Book Value
C$10.68 per share

Miscellaneous

Free Float
N/A
Market Cap
C$15.61 million
Optionable
Not Optionable
Beta
2.26
These 7 Stocks Will Be Magnificent in 2024 Cover

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

This page (TSE:AEZS) was last updated on 11/2/2024 by MarketBeat.com Staff
From Our Partners